» Articles » PMID: 24661247

Data-driven Grading of Brain Gliomas: a Multiparametric MR Imaging Study

Overview
Journal Radiology
Specialty Radiology
Date 2014 Mar 26
PMID 24661247
Citations 41
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To grade brain gliomas by using a data-driven analysis of multiparametric magnetic resonance (MR) imaging, taking into account the heterogeneity of the lesions at MR imaging, and to compare these results with the most widespread current radiologic reporting methods.

Materials And Methods: One hundred eighteen patients with histologically confirmed brain gliomas were evaluated retrospectively. Conventional and advanced MR sequences (perfusion-weighted imaging, MR spectroscopy, and diffusion-tensor imaging) were performed. Three evaluations were conducted: semiquantitative (based on conventional and advanced sequences with reported cutoffs), qualitative (exclusively based on conventional MR imaging), and quantitative. For quantitative analysis, four volumes of interest were placed: regions with contrast material enhancement, regions with highest and lowest signal intensity on T2-weighted images, and regions of most restricted diffusivity. Statistical analysis included t test, receiver operating characteristic (ROC) analysis, discriminant function analysis (DFA), leave-one-out cross-validation, and Kendall coefficient of concordance.

Results: Significant differences were noted in age, relative cerebral blood volume (rCBV) in contrast-enhanced regions (cutoff > 2.59; sensitivity, 80%; specificity, 91%; area under the ROC curve [AUC] = 0.937; P = .0001), areas of lowest signal intensity on T2-weighted images (>2.45, 57%, 97%, 0.852, and P = .0001, respectively), restricted diffusivity regions (>2.61, 54%, 97%, 0.808, and P = .0001, respectively), and choline/creatine ratio in regions with the lowest signal intensity on T2-weighted images (>2.07, 49%, 88%, 0.685, and P = .0007, respectively). DFA that included age; rCBV in contrast-enhanced regions, areas of lowest signal intensity on T2-weighted images, and areas of restricted diffusivity; and choline/creatine ratio in areas with lowest signal intensity on T2-weighted images was used to classify 95% of patients correctly. Quantitative analysis showed a higher concordance with histologic findings than qualitative and semiquantitative methods (P < .0001).

Conclusion: A quantitative multiparametric MR imaging evaluation that incorporated heterogeneity at MR imaging significantly improved discrimination between low- and high-grade brain gliomas with a very high AUC (ie, 0.95), thus reducing the risk of inappropriate or delayed surgery, respectively.

Citing Articles

Deep learning models for rapid discrimination of high-grade gliomas from solitary brain metastases using multi-plane T1-weighted contrast-enhanced (T1CE) images.

Xiong Z, Qiu J, Liang Q, Jiang J, Zhao K, Chang H Quant Imaging Med Surg. 2024; 14(8):5762-5773.

PMID: 39144024 PMC: 11320514. DOI: 10.21037/qims-24-380.


Magnetic Resonance Spectroscopy of Intra-axial Gliomas With Histopathological Correlation in a Tertiary Care Center of Eastern Nepal.

Tiwari S, Gyawali I Cureus. 2024; 16(2):e54287.

PMID: 38496065 PMC: 10944577. DOI: 10.7759/cureus.54287.


Predicting Rectal Cancer Response to Total Neoadjuvant Treatment Using an Artificial Intelligence Model Based on Magnetic Resonance Imaging and Clinical Data.

Ouyang G, Chen Z, Dou M, Luo X, Wen H, Deng X Technol Cancer Res Treat. 2023; 22:15330338231186467.

PMID: 37431270 PMC: 10338728. DOI: 10.1177/15330338231186467.


Conventional and Advanced Magnetic Resonance Imaging Assessment of Non-Enhancing Peritumoral Area in Brain Tumor.

Scola E, Del Vecchio G, Busto G, Bianchi A, Desideri I, Gadda D Cancers (Basel). 2023; 15(11).

PMID: 37296953 PMC: 10252005. DOI: 10.3390/cancers15112992.


Developing a Predictive Grading Model for Children with Gliomas Based on Diffusion Kurtosis Imaging Metrics: Accuracy and Clinical Correlations with Patient Survival.

Voicu I, Napolitano A, Caulo M, Dotta F, Piccirilli E, Vinci M Cancers (Basel). 2022; 14(19).

PMID: 36230701 PMC: 9563289. DOI: 10.3390/cancers14194778.